Drug intelligence / Profile preview

MK-0999

Development stage: Unknown
Lead developer: Merck
Modality: Small Molecules
Administration: Intravenous

Overview

MK-0999 is a compound initially developed by Merck Sharp & Dohme. It is described as a PET imaging drug, with its highest reported R&D status as "Pending." The specific mechanism of action is related to its use in positron emission tomography (PET) imaging, but further details on molecular targets or clinical indications are not provided in the available sources[1]. There is no evidence that it has reached advanced clinical development or approval for any indication.

Targets

TACR1 (Neurokinin‑1 Receptor)

Beyond the preview

Go deeper on MK-0999.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MK-0999.

Explore the full profile